SCHEMBL4207016

SCHEMBL4207016

CCCN(CCC)CCCCNCc1ccc(C(=O)C(C)(Cc2ncc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.70
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
S1PR1 P21453 4/20 0.33
S1PR3 Q99500 4/20 0.33
S1PR2 O95136 3/20 0.33
LPAR2 Q9HBW0 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CA2 P00918 1/20 0.33
NAMPT P43490 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1793193 0.82 CXCR4 (1.00) CXCR4DRD2DRD4DRD3
SCHEMBL1792747 0.82 CXCR4 (0.98) CXCR4DRD2DRD4DRD3
SCHEMBL4198764 0.82 CXCR4 (0.71) CXCR4DRD2DRD4DRD3S1PR1
SCHEMBL12507647 0.79 CXCR4 (0.68) CXCR4DRD2DRD4DRD3NAMPT
SCHEMBL1797198 0.79 CXCR4 (0.94) CXCR4
SCHEMBL4209786 0.79 CXCR4 (0.67) CXCR4DRD2DRD4DRD3NAMPT
SCHEMBL1204806 0.78 CXCR4 (0.72) CXCR4HRH4HRH3SMN1; SMN2
Ethyl Acetate SCHEMBL2204091 0.78 CXCR4 (0.66) CXCR4DRD2DRD4DRD3S1PR1
SCHEMBL2694469 0.77 CXCR4 (0.76) CXCR4S1PR1S1PR3S1PR2NAMPT
SCHEMBL4196900 0.77 CXCR4 (0.64) CXCR4S1PR1S1PR3S1PR2HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871210-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-10-28 US disclosed
US-20140072576-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-13 US disclosed
US-8614323-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-12-24 US disclosed
EP-2657235-A1 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-10-30 EP disclosed
US-20120328627-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-12-27 US disclosed
US-8318931-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-11-27 US disclosed
US-8293896-B2 2012-10-23 US disclosed
US-20090118279-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-05-07 US disclosed
EP-1942108-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140072576-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR1, CXCR3 CXCR4 1/4885DRD2 2051/4885DRD4 3058/4885
US-20090118279-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CXCR1, CXCR3 CXCR4 1/4885DRD2 2148/4885DRD4 2771/4885
US-20120328627-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR1, CXCR3 CXCR4 1/4885DRD2 2051/4885DRD4 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.